Condition: Tuberculosis, Pulmonary · Sponsor: Quratis Inc.
The purpose of this study is to evaluate the safety and explore the immunogenicity of ID93+GLA-SE compared to placebo following three intramuscular (IM) injections on Days 0, 28 and 56 in the Bacillus Calmette-Guérin (BCG)-vaccinated older adults aged 55 to 74 with negative or positive result on the QuantiFERON-TB (QFT) test. Eligible participants will be randomly assigned based on age group and the QFT test results to receive either QTP101 (Dose 1 and Dose 2) or placebo. Safety and immunogenicity will be monitored from the first dose until 12 months after the final dose of the investigational product. Blood samples for immunogenicity analysis will be collected at five-time points: before the first dose (Day 0), 4 weeks after the first dose (Day 28), 4 weeks after the second dose (Day 56), 4 weeks after the third dose (Day 84), and 48 weeks after the third dose (Day 392). Once the safety and immunogenicity follow-up is completed 48 weeks after the third dose (Day 392) for the last enrolled participant, a final report will be compiled based on the collected data.
This description comes directly from the study's public registry record.
Jinhee Lee, DVM, PhD · +82-2-569-3378 · lee8583@quratis.com
Always discuss trial participation with your own doctor first.
| Chung-Ang University Gwangmyeong Hospital | Gwangmyeong, Gyeonggi-do, South Korea | Recruiting |
| Yonsei University Severance Hospital | Seoul, South Korea | Recruiting |
| The Catholic University of Korea Seoul ST.MARY'S Hospital | Seoul, South Korea | Recruiting |
| Ajou University Hospital | Suwon, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06714513